Table 1.
Characteristics of Cases Included in This Study
| Characteristic | Total (n = 140) | Controls (n = 73) | PDAC (n = 67) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 58 (41.4) | 24 (32.9) | 34 (50.7) |
| Female | 63 (45.0) | 30 (41.1) | 33 (49.3) |
| Unknown | 19 (13.6) | 19 (26.0) | 0 (0.0) |
| Age, years, mean (range)∗ | 63 (27–89) | 58 (27–84) | 67 (44–89) |
| Race/ethnicity, n (%)∗ | |||
| Caucasian | 100 (71.4) | 42 (57.5) | 58 (86.6) |
| African American | 12 (8.6) | 7 (9.6) | 5 (7.5) |
| Hispanic/Latino | 2 (1.4) | 1 (1.4) | 1 (1.5) |
| Asian | 2 (1.4) | 2 (2.7) | 0 (0.0) |
| Other/unknown | 24 (17.1) | 21 (28.8) | 3 (4.5) |
| AJCC stage, n (%) | |||
| IA | 5 | NA | 5 (7.5) |
| IB | 9 | NA | 9 (13.4) |
| IIA | 1 | NA | 1 (1.5) |
| IIB | 22 | NA | 22 (32.8) |
| III | 11 | NA | 11 (16.4) |
| IV | 19 | NA | 19 (28.4) |
| Neoadjuvant chemotherapy, n (%) | 34 | NA | 34 (50.7) |
The controls include both healthy (n = 19) and disease controls (n = 54).
AJCC, American Joint Committee on Cancer; IPMN, intraductal papillary mucinous neoplasm; NA, not applicable; PDAC, pancreatic ductal adenocarcinoma.
∗
Age and race information were not collected from healthy controls.